Administrative Core

行政核心

基本信息

  • 批准号:
    10398387
  • 负责人:
  • 金额:
    $ 66.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-23 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Chronic pain is a leading cause of disability, affecting about one-third of adults worldwide, with a prevalence greater than heart disease, cancer, and diabetes combined. Misuse and abuse of opiates have led to a nationwide addiction and overdose crisis. Thus, there is an urgent need for alternative, non-addictive analgesics. Non-selective voltage-gated sodium channel (Nav) blockers are among existing non-addictive FDA-approved drugs which can sometimes provide symptomatic relief for patients. However, their utility is limited by CNS and cardiac side effects. Genetic and functional studies of human pain disorders and animal models of pain have validated NaV1.7, a voltage-gated Na Channel that is preferentially expressed in peripheral neurons, as an attractive target for therapy. Isoform-selective Nav blockers, however, are difficult to generate and those that have been generated are rapidly cleared from the body, limiting their effectiveness. Alternative approaches are needed. We propose a novel, non-addictive approach to treat chronic pain by editing the messages that encode NaV1.7 in order to alter its electrophysiological properties. By changing a single lysine codon to arginine in the ion selectivity filter, the channel will go from being Na+ selective to both Na+ and K+ selective, effectively creating a counter-current shunt that will dampen excitability. Site-Directed RNA Editing (SDRE) refers to novel mechanisms to generate programmed edits within RNAs. It relies on the ADAR (Adenosine Deaminase that Acts on RNA) enzymes, which are endogenously expressed in human cells, including sensory neurons. Directed by a guide RNA (gRNA), SDRE systems convert precisely selected adenosines to inosine, a translational mimic for guanosine, which can recode specific amino acids. For use as an analgesic, editing mRNA is preferable to DNA because it is transient, thus limiting potential off-target effects, including malignant transformations and ADARs are endogenous while enzymes for DNA manipulation (e.g. Cas proteins) are not, thus SDRE will not be as immunogenic. Compared to small molecule channel blockers, SDRE can be more specific, because it relies on Watson-Crick base-pairing of gRNAs for targeting, and its effects are likely longer lasting because they will remain as long as the edited channels are expressed. We propose to use SDRE to edit NaV1.7 K1395R to render the channel permeable to both Na+ and K+. The purpose of the Administrative Core is to develop an administrative structure to support the goals of the project. This includes committees and guidelines for keeping track of scientific milestones, resolving conflicts in intellectual property and other areas, overseeing budgets and finances, and ensuring accurate and timely reporting to the NIH.
慢性疼痛是导致残疾的主要原因,影响全球约三分之一的成年人, 比心脏病、癌症和糖尿病加起来还要严重。滥用和滥用阿片类药物导致了 全国性的吸毒过量危机因此,迫切需要替代的非成瘾性镇痛剂。 非选择性电压门控钠通道(Nav)阻滞剂是FDA批准的现有非成瘾性药物之一。 有时可以缓解患者症状的药物。然而,它们的实用性受到CNS的限制, 心脏副作用对人类疼痛障碍和疼痛动物模型的遗传和功能研究, 经验证的NaV1.7是一种优先在外周神经元中表达的电压门控Na通道, 有吸引力的治疗目标。然而,亚型选择性Nav阻断剂难以产生, 产生的毒素迅速从体内清除,限制了它们的有效性。替代方法有 needed.我们提出了一种新的,非成瘾性的方法来治疗慢性疼痛,通过编辑编码的信息, NaV1.7,以改变其电生理特性。通过改变一个单一的赖氨酸密码子精氨酸在 离子选择性过滤器,通道将从Na+选择性变为Na+和K+选择性,有效地产生 一个能抑制兴奋性的逆流分流器 定点RNA编辑(SDRE)是指在RNA内产生程序化编辑的新机制。它 依赖于阿达尔(作用于RNA的腺苷脱氨酶)酶,其在细胞中内源性表达。 人类细胞,包括感觉神经元。在向导RNA(gRNA)的指导下,SDRE系统精确地转化 选择的腺苷转化为肌苷,肌苷是鸟苷的翻译模拟物,可以重新编码特定的氨基酸。为 作为止痛药,编辑mRNA优于DNA,因为它是瞬时的,从而限制了潜在的脱靶 影响,包括恶性转化和ADAR是内源性的,而DNA操作酶 (e.g. Cas蛋白)不是,因此SDRE不会具有免疫原性。与小分子通道相比 阻断剂,SDRE可以更特异,因为它依赖于gRNA的沃森-克里克碱基配对用于靶向, 并且其效果可能持续更长时间,因为只要编辑的频道被表达,它们就将保持。 我们建议使用SDRE来编辑NaV1.7 K1395 R,以使通道对Na+和K+都是可渗透的。的 行政核心的目的是建立一个行政结构,以支持项目的目标。 这包括委员会和指导方针,以跟踪科学里程碑,解决冲突, 知识产权和其他领域,监督预算和财务,并确保准确和及时 向NIH报告。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSHUA J.C. ROSENTHAL其他文献

JOSHUA J.C. ROSENTHAL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSHUA J.C. ROSENTHAL', 18)}}的其他基金

Development and Validation of Animal Models and/or Outcome Measures
动物模型和/或结果测量的开发和验证
  • 批准号:
    10398390
  • 财政年份:
    2021
  • 资助金额:
    $ 66.65万
  • 项目类别:
Correction of Mutations Underlying Alternating Hemiplegia of Childhood by Site-Directed RNA Editing
通过定点 RNA 编辑纠正儿童交替性偏瘫的突变
  • 批准号:
    10354983
  • 财政年份:
    2021
  • 资助金额:
    $ 66.65万
  • 项目类别:
Assay Development, Screening and Early Optimization
检测方法开发、筛选和早期优化
  • 批准号:
    10398391
  • 财政年份:
    2021
  • 资助金额:
    $ 66.65万
  • 项目类别:
Center for Neuroplasticity at the University of Puerto Rico
波多黎各大学神经可塑性中心
  • 批准号:
    8687677
  • 财政年份:
    2013
  • 资助金额:
    $ 66.65万
  • 项目类别:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
活动
  • 批准号:
    8357162
  • 财政年份:
    2011
  • 资助金额:
    $ 66.65万
  • 项目类别:
Regulation of the Na/K Pump by RNA Editing
RNA 编辑对 Na/K 泵的调节
  • 批准号:
    7885009
  • 财政年份:
    2010
  • 资助金额:
    $ 66.65万
  • 项目类别:
Regulation of the Na/K Pump by RNA Editing
RNA 编辑对 Na/K 泵的调节
  • 批准号:
    8512811
  • 财政年份:
    2010
  • 资助金额:
    $ 66.65万
  • 项目类别:
Regulation of the Na/K Pump by RNA Editing
RNA 编辑对 Na/K 泵的调节
  • 批准号:
    8702244
  • 财政年份:
    2010
  • 资助金额:
    $ 66.65万
  • 项目类别:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
活动
  • 批准号:
    8166216
  • 财政年份:
    2010
  • 资助金额:
    $ 66.65万
  • 项目类别:
Regulation of the Na/K Pump by RNA Editing
RNA 编辑对 Na/K 泵的调节
  • 批准号:
    8038271
  • 财政年份:
    2010
  • 资助金额:
    $ 66.65万
  • 项目类别:

相似国自然基金

细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
  • 批准号:
    81570244
  • 批准年份:
    2015
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
  • 批准号:
    81171113
  • 批准年份:
    2011
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目

相似海外基金

Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer
靶向 A2B 腺苷受体用于胰腺癌的免疫预防
  • 批准号:
    10929664
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
Exploring the role of adenosine A2A receptors in Schizophrenia using opto-pharmacologically controlled allosteric modulation.
利用光药理学控制的变构调节探索腺苷 A2A 受体在精神分裂症中的作用。
  • 批准号:
    23K14685
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Role of Adenosine Kinase in Mixed Diastolic Heart Failure and Alzheimer Disease
腺苷激酶在混合性舒张性心力衰竭和阿尔茨海默病中的作用
  • 批准号:
    10679989
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
Allostery-driven G protein selectivity in the adenosine A1 receptor
腺苷 A1 受体中变构驱动的 G 蛋白选择性
  • 批准号:
    BB/W016974/1
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
    Research Grant
Investigation of new test methods for adenosine-sensitive atrioventricular block
腺苷敏感型房室传导阻滞新检测方法的探讨
  • 批准号:
    23K07566
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing the role of adenosine pathway in SIV pathogenesis
探讨腺苷途径在 SIV 发病机制中的作用
  • 批准号:
    10760676
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
The role of A1 adenosine receptor signaling in the decline of S. pneumoniae killing by neutrophils in vaccinated aged hosts
A1 腺苷受体信号传导在疫苗接种老年宿主中中性粒细胞杀伤肺炎链球菌下降中的作用
  • 批准号:
    10605737
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
Adenosine triphosphate as a master variable for biomass in the oceanographic context
三磷酸腺苷作为海洋学背景下生物量的主变量
  • 批准号:
    2319114
  • 财政年份:
    2023
  • 资助金额:
    $ 66.65万
  • 项目类别:
    Standard Grant
Late-Stage Functionalisation of Cyclic Guanosine Monophosphate - Adenosine Monophosphate
环单磷酸鸟苷-单磷酸腺苷的后期功能化
  • 批准号:
    2751533
  • 财政年份:
    2022
  • 资助金额:
    $ 66.65万
  • 项目类别:
    Studentship
Postnatal development of adenosine kinase in the brainstem network that controls breathing
控制呼吸的脑干网络中腺苷激酶的出生后发育
  • 批准号:
    573323-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 66.65万
  • 项目类别:
    University Undergraduate Student Research Awards
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了